ARTICLE | Clinical News
VicOryx: Phase I/IIa data
March 16, 2015 7:00 AM UTC
An open-label, German Phase I/IIa trial in 26 patients with p16INK4a-overexpressing HPV-positive cancer showed that once-weekly subcutaneous 100 ug VicOryx plus the Montanide ISA 51 VG adjuvant for th...